1. Sartor O, de Bono J, Chi KN, et al: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091-1103, 2021 2. Garje R, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASC...
ASCO建议 基于此前数个研究,专家组建议:对之前使用过一种雄激素受体抑制剂和至少一种化疗药物,且PSMA PET/ CT阳性的mCRPC患者,将177Lu-PSMA-617 IV作为此类患者的一种治疗选择,每6周1次,应用4-6个周期。(类型:基于循证医学,利大于弊;证据质量:中等;推荐度:强) 1.1 专家组建议患者应选择PSMA PET。(类型:...
参考文献: [1]Chi KN, Armstrong AJ, Krause BJ, et al. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024;85(4):382...
原文出处:Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。
68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;10:2273–83. https://doi.org/10.7150/thno.38501. Article CAS PubMed PubMed Central Google Scholar Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Ping...
放射性同位素的辐射仅在很短的距离内发挥作用,以限制对周围细胞的损害。(生物谷Bioon.com) 原文出处:Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
The FDA has approved lutetium-177 (177Lu)-PSMA-617 (Pluvicto) to treat patients with metastatic castration-resistant prostate cancer (mCRPC) following androgen receptor pathway inhibition and taxane-based chemotherapy.1 Findings from the phase 3 VISION trial (NCT03511664) supported the regulatory...
Overall, the open-label, multi-center, phase 3 PSMAfore study enrolled 469 patients with PSMA-positive mCRPC who progressed only once after treatment with a second-generation ARPI. Patients were randomized in a 1:1 ratio to 177Lu-PSMA-617 or a change in ARPI. The primary end point is rPF...
(1/18) phase 3 trial of [177lu]lu-psma-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (psmafore) 4 17:00 大咖指导点评(一) 0 27:00 psma targeted theranostics for prostate cancer 0 12:00 大咖指导点评(二) 0 26:00 在egfr外显子20突变nsclc患者中比较ami...
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial 来自 国家科技图书文献中心 喜欢 0 阅读量: 1 作者:MS Hofman,L Emmett,S Sandhu,A Iravani,JP Buteau,AM Joshua...